Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Raised to $8.00 at UBS Group

Perspective Therapeutics (NYSEAMERICAN:CATX) had its price objective upped by UBS Group from $7.00 to $8.00 in a research report issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price suggests a potential upside of 61.62% from the company’s current price.

Several other equities research analysts also recently commented on CATX. Piper Sandler began coverage on Perspective Therapeutics in a report on Thursday, February 19th. They set an “overweight” rating and a $16.00 target price for the company. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday. HC Wainwright lifted their target price on shares of Perspective Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. BTIG Research restated a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday. Finally, Royal Bank Of Canada reduced their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating for the company in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat, Perspective Therapeutics has an average rating of “Buy” and an average target price of $12.25.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN:CATX opened at $4.95 on Wednesday. The firm’s 50 day moving average is $4.26 and its two-hundred day moving average is $3.42. Perspective Therapeutics has a 52 week low of $1.60 and a 52 week high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.66 and a current ratio of 8.66.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its earnings results on Monday, March 16th. The company reported ($0.51) EPS for the quarter. The business had revenue of $0.04 million during the quarter. Perspective Therapeutics had a negative net margin of 9,841.86% and a negative return on equity of 40.03%. As a group, analysts expect that Perspective Therapeutics will post -0.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CATX. AXQ Capital LP grew its stake in shares of Perspective Therapeutics by 24.2% during the fourth quarter. AXQ Capital LP now owns 12,749 shares of the company’s stock valued at $35,000 after purchasing an additional 2,481 shares during the last quarter. Deutsche Bank AG boosted its stake in shares of Perspective Therapeutics by 6.1% in the 4th quarter. Deutsche Bank AG now owns 54,245 shares of the company’s stock valued at $149,000 after purchasing an additional 3,119 shares during the last quarter. Vontobel Holding Ltd. raised its position in shares of Perspective Therapeutics by 25.0% during the 4th quarter. Vontobel Holding Ltd. now owns 25,000 shares of the company’s stock valued at $69,000 after acquiring an additional 5,000 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Perspective Therapeutics by 184.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after purchasing an additional 5,475 shares during the period. Finally, Taylor & Morgan Wealth Management LLC boosted its position in shares of Perspective Therapeutics by 6.6% in the 4th quarter. Taylor & Morgan Wealth Management LLC now owns 97,000 shares of the company’s stock worth $267,000 after purchasing an additional 6,000 shares during the last quarter. 54.66% of the stock is owned by institutional investors.

More Perspective Therapeutics News

Here are the key news stories impacting Perspective Therapeutics this week:

• Positive Sentiment: Updated [212Pb]VMT-α-NET data accepted for a poster at the AACR Annual Meeting (presentation scheduled April 20). Prior interim data showed no dose‑limiting toxicities, no serious renal issues, and encouraging anti‑tumor activity (76% without progression in an analyzed cohort), which supports the program’s clinical momentum and visibility in oncology. AACR Data Acceptance
• Positive Sentiment: BTIG Research reaffirmed a “Buy” rating and set a $14 price target, signaling continued analyst conviction and providing upside vs. current levels. BTIG Reaffirmation
• Neutral Sentiment: Perspective issued a full-year 2025 results and business highlights update describing progress across its neuroendocrine, melanoma and solid tumor programs and growth of regional finishing facilities; useful for monitoring program cadence but not a near-term revenue driver. Full Year 2025 Results
• Neutral Sentiment: The company is scheduled to release its quarterly earnings on Wednesday — an event that could trigger near-term volatility as investors parse operational and cash‑flow details. Earnings Release Notice
• Negative Sentiment: Latest quarter: reported a ($0.51) EPS and only $0.04M in revenue, with very negative margins and ROE — highlighting ongoing cash burn and dependence on financing or milestones to fund development. This is the principal near‑term negative catalyst pressuring the stock. Quarterly Results
• Negative Sentiment: RBC cut its price target from $18 to $14 (still an Outperform) — a downward revision that tempers upside expectations despite the maintained positive rating. RBC Target Cut

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.